Using Artificial Intelligence in Drug Discovery.

By Ben Paice By Ben Paice

Artificial Intelligence is one of the most exciting topics of conversation across every industry. And there are few more exciting applications for AI in the life science space than in harnessing it for drug discovery.

We're only just scratching the surface for AI in this market, but to find out more, CM Life Science hosted a webinar featuring three experts in the AI drug discovery space.

We were joined by:

Daniel Meyer - Daniel is CEO of CellChorus, the leader in providing high-throughput dynamic single-cell analysis to the life sciences industry and pioneering the use of AI through their bespoke visual AI platform.

Andrew Radin - Andrew is Co-Founder and Chief Executive Officer of twoXAR (pronounced: “two-czar”), an AI-powered drug discovery and development company focused on first-in-class small molecules.

Brad Pryde - Brad is Co-Founder & COO at OneThree Biotech, a VC backed startup working to change how new medicines are discovered using biology-driven AI.

As CM Life Science's specialist in data science & bioinformatics, I hosted the event and enjoyed it thoroughly. If you have any questions about the webinar or my contacts in this space, please email me at Ben.Paice@lifesci-sm.com.

For more content like this, visit my consultant page.

Recommended.

Get the latest into your inbox.